Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
Add more filters










Publication year range
1.
J Microencapsul ; 22(2): 153-65, 2005 Mar.
Article in English | MEDLINE | ID: mdl-16019901

ABSTRACT

The irritation effects of ibuprofen, a widely used non-steroidal anti-inflammatory drug (NSAID), were evaluated on mouse gastric and duodenal mucosa when suspended in 0.5% (w/v) sodiumcarboxymethylcellulose (NaCMC) solution and loaded in alginate beads. The ionotropic gelation method was used to prepare controlled release alginate beads of ibuprofen. The influence of various formulation factors on the encapsulation efficiency, as in vitro drug release and micromeritic properties, was investigated. Other variables included the alginate concentration, percentage drug loading and stirring speed during the microencapsulation process. Scanning electron micrographs of alginate beads loaded with ibuprofen showed rough surface morphology and particle sizes in the range of 1.15 +/- 0.4 - 3.15 +/- 0.6 mm. The yield of microspheres, as collected after drying, was generally 80-90%. Formulation code H showing t50% value of 3.5 h was chosen for in vivo trials because of the appropriate drug release properties. For in vivo trials, free ibuprofen (100 mg kg(-1)), blank and ibuprofen (100 mg kg(-1)) loaded alginate beads (formulation code H) were suspended in 0.5% (w/v) NaCMC solution and each group was given to six mice orally by gavage. NaCMC solution was used as a control in experimental studies. In vivo data showed that the administration of ibuprofen in alginate beads prevented the gastric lesions.


Subject(s)
Alginates , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Drug Compounding/methods , Ibuprofen/pharmacology , Microspheres , Animals , Biocompatible Materials , Biodegradation, Environmental , Carboxymethylcellulose Sodium , Delayed-Action Preparations/pharmacology , Duodenum/drug effects , Female , Gastric Mucosa/drug effects , Intestinal Mucosa/drug effects , Mice , Microscopy, Electron, Scanning/methods , Particle Size , Surface Properties
2.
J Microencapsul ; 20(6): 705-17, 2003.
Article in English | MEDLINE | ID: mdl-14594660

ABSTRACT

Chronic osteomyelitis is still the cause of many problems in orthopaedics in terms of therapy and infection persistence. Four-to-six week systemic antibiotic therapy is required along with bone and soft tissue debridement in the therapy of chronic osteomyelitis. Prolonged-release local antibiotic therapy has been taken into consideration due to the side effects encountered in long-term high dose antibiotic use and the duration of hospitalization of the patients. Although local antibiotic therapy has been achieved by bone cement, a second surgical operation is needed for the removal of the system. On the other hand, heat generation during cement curing limits the use of heat-sensitive active ingredients. The most frequent osteomyelitis inducing micro-organism is gram (+) Staphylococcus aureus. In this study, teicoplanin, a glycopeptide antibiotic, active on gram (+) bacteria, was incorporated in a synthetic polymer in order to prepare a microsphere formulation for implantation to bone defects. Particle size, surface characteristics, loading capacity and in vitro release characteristics of the microspheres were determined as well as stability assessment of teicoplanin under accelerated conditions. In vivo studies were performed on rabbits and the microparticles were implanted intra-articularly to the lateral condylus of the femur. Antibiotic presence was detected by a microbiological assay from synovial fluid sample aspirated throughout 5 weeks. In the light of these evaluations, microspheres prepared from PLGA (75:25) (Mw 136,000) polymer were determined to be effective, and promising for obtaining prolonged local antibiotic release.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Bone Diseases, Infectious/drug therapy , Microspheres , Teicoplanin/administration & dosage , Animals , Anti-Bacterial Agents/analysis , Biocompatible Materials , Biodegradation, Environmental , Delayed-Action Preparations , Drug Carriers , Drug Compounding/methods , Lactic Acid , Microbial Sensitivity Tests/methods , Microscopy, Electron, Scanning/methods , Osteomyelitis/complications , Particle Size , Polyglycolic Acid , Polylactic Acid-Polyglycolic Acid Copolymer , Polymers , Rabbits , Staphylococcal Infections/drug therapy , Synovial Fluid/metabolism , Teicoplanin/analysis , Time Factors
3.
J Microencapsul ; 20(2): 261-71, 2003.
Article in English | MEDLINE | ID: mdl-12554379

ABSTRACT

Terbutaline sulphate (TBS) is widely used in the treatment of bronchial asthma, chronic bronchitis and emphysema. Because of its short biological half life and dosing schedule, a long acting TBS formulation is required to improve patient compliance. The objective of this study was to develop a TBS containing biodegradable microsphere formulation. Poly(D,L-lactide-co-glycolide) (PLGA) and poly(L-lactic acid) (L-PLA) were chosen as matrix materials. A solvent evaporation method was used for preparation of microspheres. Surface morphology, particle size distribution and encapsulation efficiency were investigated. In vitro release studies were performed in pH 7.4 phosphate buffer. In vitro distribution of microspheres were studied in the Swiss albino male mice. All microspheres were spherical in shape and had a porous surface with mean diameters of 9-21 microm. The encapsulation efficiency was influenced by the polymer type, but not the molecular weight. About 90% of the initial amount was trapped in PLGA microspheres, and the remainder was on the surface. In the case of L-PLA, 50% of the total drug was associated with the surface of microspheres. The In vitro release pattern was biphasic characterized by an initial burst phase followed by a slower phase. The L-PLA microspheres released approximately 92% of the initial payload in 72 h. On the other hand, TBS release was increased with an increase in the molecular weight of PLGA. Biodistribution of L-PLA microspheres was characterized by an initially high uptake (35%) by the lungs. All these results suggest that L-PLA and PLGA microspheres have the potential to be used for passive lung targeting.


Subject(s)
Bronchodilator Agents/chemistry , Lactic Acid , Polyglycolic Acid , Polymers , Terbutaline/chemistry , Biodegradation, Environmental , Biopolymers , Bronchodilator Agents/pharmacokinetics , Chromatography, Gel/methods , Microspheres , Particle Size , Polylactic Acid-Polyglycolic Acid Copolymer , Solubility , Terbutaline/pharmacokinetics
4.
J Microencapsul ; 19(4): 473-84, 2002.
Article in English | MEDLINE | ID: mdl-12396384

ABSTRACT

The aim of this study was to formulate biodegradable microspheres containing an anti-parkinsonian agent, bromocryptine mesylate, for brain delivery. The effect of formulation parameters (e.g. polymer, emulsifying agent type and concentration) on the characteristics of the microspheres produced, the efficiency of drug encapsulation, the particle size distribution and in vitro drug release rates from the bromocryptine mesylate microspheres were investigated using a 3(2) factorial design. Bromocryptine mesylate was encapsulated into biodegradable polymers using the following three different polymers; poly(L-lactide), poly(D,L-lactide) and poly(D,L-lactide-co-glycolide). The SEM photomicrographs showed that the morphology of the microspheres greatly depended on the polymer and emulsifying agent. The results indicate that, regardless of the polymer type, increase in emulsifying agent concentration from 0.25-0.75% w/v markedly decreases the particle size of the microspheres. Determination of particle size revealed that the use of 0.75% w/v of emulsifying agent concentration and a polymer solution concentration of 10% w/v resulted in optimum particle size. In order to prepare biodegradable microspheres with high drug content and small particle size, selection of polymer concentration as well as emulsifying agent concentration is critical. Polymer type has a less pronounced effect on the percentage encapsulation efficiency and particle size of microspheres than on the t(50%). The microspheres prepared by all three polymers, at a polymer concentration of 10% w/v and an emulsifying agent concentration of 0.75% w/v with NaCMC:SO (4:1, w/v) mixture was as the optimum formulation.


Subject(s)
Bromocriptine/administration & dosage , Drug Compounding/methods , Biodegradation, Environmental , Brain/metabolism , Bromocriptine/pharmacokinetics , Drug Delivery Systems , Excipients , Humans , In Vitro Techniques , Lactic Acid , Microscopy, Electron, Scanning , Microspheres , Particle Size , Polyesters , Polyglycolic Acid , Polylactic Acid-Polyglycolic Acid Copolymer , Polymers , Solvents
5.
J Microencapsul ; 18(5): 603-12, 2001.
Article in English | MEDLINE | ID: mdl-11508766

ABSTRACT

Dexamethasone sodium phosphate (DSP) is a widely used corticosteroid in the treatment of brain oedema associated with brain tumours. DSP has many side effects that limit its usage at an effective concentration. The objective of this study was to minimize these side effects by encapsulating DSP using biodegradable synthetic polymers, to extend the release time from microspheres and to evaluate the effectiveness in the treatment of brain oedema. Microspheres containing 5% DSP were formulated by the solvent evaporation method by using a 1:1 mixture of two synthetic polymers, poly(lactic-co-glycolic acid) and L-polylactic acid (PLGA and L-PLA). The surface morphologies and particle size distribution of the microspheres were investigated. The in-vitro release studies were performed in pH 7.4 phosphate buffer solution. For determining the effectiveness of microspheres in the treatment of brain oedema, Sprague-Dawley rats weighing 200-250g were used as an animal model. Brain oedema was generated by the cold lesion method, and the effectiveness of the microspheres in treatment of oedema was investigated by the wet-dry weight method, lipid peroxidation ratios and histological evaluations. The average particle size of the microspheres was 13.04 +/- 2.05 microm, and the in-vitro release time of the microspheres was 8 h for 100/release. The degree of oedema was significantly different from the control group for the wet-dry weight method and lipid peroxidation ratio (p < 0.05). Similarly, histological evaluation of the tissues shoved that degree of oedema was significantly decreased with respect to the control group. All these results showed that implantation of microspheres was significantly more effective with respect to the systemic administration of DSP.


Subject(s)
Brain Edema/drug therapy , Dexamethasone/analogs & derivatives , Dexamethasone/administration & dosage , Lactic Acid/administration & dosage , Polyglycolic Acid/administration & dosage , Polymers/administration & dosage , Animals , Brain/drug effects , Brain/metabolism , Brain Edema/metabolism , Dexamethasone/chemistry , Lipid Peroxidation , Microspheres , Particle Size , Polyesters , Polylactic Acid-Polyglycolic Acid Copolymer , Rats , Solubility
6.
J Microencapsul ; 18(4): 443-56, 2001.
Article in English | MEDLINE | ID: mdl-11428674

ABSTRACT

The dispersion of non-steroidal antiinflammatory drugs (NSAIDs) into biodegradable polymeric matrices have been accepted as a good approach for obtaining a therapeutic effect in a predetermined period of time meanwhile minimizing the side effects of NSAIDs. In the present study, it was aimed to prepare Naproxen Sodium (NS), (a NSAID) loaded microsphere formulation using natural Bovine Serum Albumin (BSA) and synthetic biodegradable polymers such as poly(lactide-co-glycolic acid) (PLGA) (50:50 MW 34,000 and 88,000 Da) for intra-articular administration, and to study the retention of the drug at the site of injection in the knee joint. NS incorporated microspheres were evaluated in vitro for particle size (the mean particle size; for BSA microspheres, 10.0 +/- 0.3 microm, for PLGA microspheres, 9.0 +/- 0.2 and 5.0 +/- 0.1 microm for MW 34,000 and 88,000 Da, respectively), yield value, drug loading, surface morphology and drug release. For in vivo studies, monoarticular arthritis was induced in the left knee joints of rabbits by using ovalbumin and Freund's Complete Adjuvant as antigen and adjuvant. A certain time (4 days) is allowed for the formation of arthritis in the knee joints, then the NS loaded microspheres were injected directly into the articular cavity. At specific time points, gamma scintigrams were obtained to determine the residence time of the microspheres in knee joints, in order to determine the most suitable formulation. This study indicated that PLGA, a synthetic polymer, is more promising than the natural type BSA microspheres for an effective cure of mono-articular arthritis in rabbits.


Subject(s)
Naproxen/administration & dosage , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/metabolism , Arthritis, Experimental/drug therapy , Biocompatible Materials , Biodegradation, Environmental , Capsules , Cattle , Drug Carriers , Drug Compounding/methods , Humans , In Vitro Techniques , Injections, Intra-Articular , Lactic Acid , Microscopy, Electron, Scanning , Naproxen/metabolism , Particle Size , Polyglycolic Acid , Polylactic Acid-Polyglycolic Acid Copolymer , Polymers , Rabbits , Serum Albumin, Bovine/administration & dosage
7.
J Microencapsul ; 17(4): 509-18, 2000.
Article in English | MEDLINE | ID: mdl-10898090

ABSTRACT

Radioembolization is used in diagnostic imaging of the lungs and for radioembolization therapy of hepatic tumours. Presently, 99mTc labelled macroaggregates or microspheres of human serum albumin (HAM) are used for this purpose. Poly lactic acid (PLA) is biodegradable, like HAM, and, unlike HAM, is not a blood product. The aim of the present study was to evaluate the uptake and biodegradation of PLA microspheres in lungs. PLA (MW = 48720 Da) microspheres of 1.0-100 microm (mean = 39.5 microm) in diameter were prepared by solvent evaporation from methylene chloride. They were labelled with 99mTc by stannous chloride reduction at pH 3, with an efficiency of 98% and a stability of 96% at 24 h. For biodistribution studies, 15 mice were i.v. injected with 20 microCi 99mTc-PLA microspheres in 0.1 ml and sacrificed at 15 min, 1, 3, 6 and 24 h (three at each time point). All the organs were removed, weighed and counted against a standard prepared from 1/100 dilution of the injected radioactivity. Some mice were similarly injected and sacrificed at 30 min, 15 and 30 days. The lungs were removed and frozen, and 10 microm sections were obtained, stained with haemotoxylin and eosin and examined under a light microscope. Five rabbits were i.v. injected with 1 mCi of 99mTc-PLA microspheres. Scintigrams were obtained at various intervals up to 24 h. In mice, the lung uptake was significant at 30 min-1h post-injection. In rabbits, the lungs were the only organs visualized up to 24 h. Microscopic examination of tissue sections demonstrated slow biodegradation of PLA particles. In conclusion; (1) The high lung uptake obtained in mice and rabbits indicates the suitability of PLA microspheres for lung imaging, and (2) although the slow biodegradation rate might be a disadvantage in patients with lung disorders in diagnostic studies, it may be an advantage in therapeutic applications with radionuclides which have long physical half lives.


Subject(s)
Lung/diagnostic imaging , Radiopharmaceuticals , Technetium , Animals , Drug Compounding , Embolization, Therapeutic , Humans , Lactic Acid , Mice , Microspheres , Particle Size , Polyesters , Polymers , Rabbits , Radionuclide Imaging , Serum Albumin , Technetium Tc 99m Aggregated Albumin , Tissue Distribution
8.
J Microencapsul ; 17(2): 145-55, 2000.
Article in English | MEDLINE | ID: mdl-10738690

ABSTRACT

The use of polymeric carriers in formulations of therapeutic drug delivery systems has gained widespread application, due to their advantage of being biodegradable and biocompatible. Among the microparticulate systems, microspheres have a special importance since it is possible to target drugs and provide controlled release. Diclofenac sodium (DS), is a potent drug in the NSAID group having non-steroidal, anti-inflammatory properties, and is widely used in the treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. In this present study, it was aimed to prepare microsphere formulations of DS using a natural biodegradable polymer as a carrier for intraarticular administration to extend the duration period of the dosage form in the knee joint. Microsphere formulations of DS which were prepared were evaluated in vitro for particle size, yield value, encapsulation efficiency, surface morphology, and in vitro drug release. Two appropriate formulations were selected for in vivo trials. For the in vivo studies, Technetium-99m labelled polyclonal human immunogammaglobulin (99mTc-HIG) was used as the radiopharmaceutical to demonstrate arthritic lesions by gamma scintigraphy. After the induction of arthritis in knee joints of rabbits, the radio-labelled microspheres loaded with DS were injected directly into the articular cavity and at specific time points gamma scintigrams were obtained to find the residence time of the microspheres in knee joints in order to determine the most suitable formulation.


Subject(s)
Arthritis, Experimental/drug therapy , Diclofenac/administration & dosage , Diclofenac/analysis , Serum Albumin, Bovine/administration & dosage , Serum Albumin, Bovine/analysis , Animals , Arthritis, Experimental/chemically induced , Arthritis, Experimental/diagnostic imaging , Biodegradation, Environmental , Chemistry, Pharmaceutical , Diclofenac/chemistry , Drug Carriers , Drug Compounding/methods , Drug Evaluation, Preclinical , Drug Stability , Emulsions/chemistry , Female , Glutaral/chemistry , Hindlimb , Immunoglobulins , Injections, Intra-Articular , Joints/drug effects , Joints/metabolism , Microspheres , Ovalbumin , Particle Size , Rabbits , Radionuclide Imaging , Radiopharmaceuticals , Serum Albumin, Bovine/chemistry , Surface Properties , Technetium
9.
Int J Pharm ; 195(1-2): 179-88, 2000 Feb 15.
Article in English | MEDLINE | ID: mdl-10675695

ABSTRACT

Recently, considerable interest has been focused on the use of biodegradable polymers for specialized applications such as controlled release of drug formulations; meanwhile, microsphere drug-delivery systems using various kinds of biodegradable polymers have been studied extensively during the past two decades. Poly (lactide-co-glycolide) (PLGA) polymers have been proven to be excellent drug carriers for microparticulate systems due to their advantages, e.g. biocompatibility and regulatory approval. The administration of nonsteroidal anti-inflammatory drugs (NSAIDs) into the intra-articular cavity in patients with chronic inflammatory disease is complicated due to the short duration of effect. In the present study, controlled-release parenteral formulations of diclofenac sodium (DS), a commonly used NSAID, were prepared for intra-articular administration, and evaluated in vitro for particle size, yield, drug loading, surface morphology and release characteristics. For in vivo studies, Technetium-99m labelled polyclonal human immunogammaglobulin (99m Tc-HIG) was used as the radiopharmaceutical to demonstrate arthritic lesions by gamma scintigraphy. Evaluation of arthritic lesions post-therapy in rabbits showed no significant difference in the group treated with PLGA (50:50) (mw 34000) DS microspheres compared to control groups.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Arthritis/drug therapy , Biocompatible Materials , Chemistry, Pharmaceutical , Diclofenac/administration & dosage , Drug Carriers , Lactic Acid , Polyglycolic Acid , Polymers , Animals , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Biodegradation, Environmental , Delayed-Action Preparations , Diclofenac/therapeutic use , Drug Carriers/chemistry , Female , Humans , Microspheres , Polylactic Acid-Polyglycolic Acid Copolymer , Rabbits
10.
J Clin Pharm Ther ; 23(1): 57-65, 1998 Feb.
Article in English | MEDLINE | ID: mdl-9756113

ABSTRACT

BACKGROUND: Intravenous lipid emulsions stabilized with phospholipids have been an attractive alternative as vehicles for drug delivery, particularly for the parenteral administration of drugs with solubility problems. METHODS: Naproxen (a poorly aqueous soluble non-steroidal anti-inflammatory agent) emulsions were formulated with different types of emulsifiers (soybean lecithin, synperonic PEF-127 and a 50:50 mixture of these). The stability of the various emulsion systems was evaluated at different temperatures (4, 25 and 40 degrees C) for a period of 6 months by measuring changes in pH, droplet size, viscosity and percentage oil separation. The percentage of naproxen incorporation and the degree of haemolysis induced by the different types of emulsion systems was also determined. RESULTS: The emulsifier type showed a pronounced effect on the physicochemical properties of the emulsion systems, whereas storage temperature and time did not. Irrespective of emulsifier type, storage temperature and time, the percentage incorporation of naproxen in emulsions was between 80 and 100%. The degree of haemolysis induced by other emulsion components (dimethylsulfoxide (DMSO) and naproxen solution in DMSO) was about 10 times higher than that induced by emulsion systems. CONCLUSION: Choice of emulsifier is the most important factor in the stability of the naproxen emulsions.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Fat Emulsions, Intravenous , Naproxen/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Chemistry, Pharmaceutical , Drug Stability , Excipients/chemistry , Humans , Hydrogen-Ion Concentration , Naproxen/chemistry , Parenteral Nutrition , Particle Size , Phosphatidylcholines/chemistry , Soybean Oil/chemistry , Temperature , Viscosity , Vitamin E/chemistry
11.
J Microencapsul ; 14(6): 689-711, 1997.
Article in English | MEDLINE | ID: mdl-9394251

ABSTRACT

Chitosan, a hydrophilic biopolymer, is obtained industrially by hydrolysing the aminoacetyl groups of chitin. It is a natural, non-toxic, biodegradable polysaccharide available as solution, flake, fine powder, bead and fibre. The sources, biochemical aspects, structure and chemical modification, physico-chemical and functional properties, and applications of chitosan have been investigated extensively in the literature. In this paper, the attractive properties and broad applications of chitosan-based microparticles, their versatile properties, different preparation methods, and pharmaceutical and biopharmaceutical applications are reviewed.


Subject(s)
Chitin/analogs & derivatives , Animals , Capsules , Chitin/chemical synthesis , Chitin/chemistry , Chitin/metabolism , Chitosan , Drug Compounding/methods , Humans , Microspheres
12.
Pharm Dev Technol ; 2(2): 151-60, 1997 May.
Article in English | MEDLINE | ID: mdl-9552441

ABSTRACT

The physicochemical properties and in vivo distribution of poly(L-lactide) (L-PLA) microspheres containing 5-fluorouracil (5-FU) prepared by a solvent evaporation method were evaluated for potential use in the treatment of liver cancers. Two different molecular weight polymers of L-PLA [L-PLA1 (152,500 Da) and L-PLA2 (52,000 Da)] were used to prepare 5-FU-loaded microspheres. The mean particle size of the microspheres was 3-6 microns, and there was a direct relationship between the mean particle size and the molecular weight of the polymers. The drug release behavior from microspheres exhibited a diffusion mechanism in different dissolution media, with the molecular weight of the polymer being a major factor in controlling the drug release and degradation rates. Following intravenous injection of 99mTc-labeled L-PLA microspheres, with or without 5-FU, or free 5-FU into mice, L-PLA2 microspheres localized mainly in the liver. The disappearance rate of radioactivity from the tissue was very slow in comparison to that of free 5-FU. The results were confirmed by histological examination of liver tissue following administration of fluorescein particles. In addition, growth of a human liver tumor as first transplant generation under the renal capsule of immunocompetent rats and antitumor activity of L-PLA2 microspheres were investigated. Histological examination by optical microscopy showed that there was no neoplastic tissue of the kidney or in other tissues examined after treatment.


Subject(s)
Antimetabolites, Antineoplastic/pharmacokinetics , Antimetabolites, Antineoplastic/therapeutic use , Drug Delivery Systems , Fluorouracil/pharmacokinetics , Fluorouracil/therapeutic use , Lactic Acid , Polymers , Animals , Biodegradation, Environmental , Chemistry, Pharmaceutical , Female , Humans , Liver Neoplasms, Experimental/drug therapy , Microspheres , Molecular Weight , Particle Size , Polyesters , Rats , Rats, Wistar , Technetium , Tissue Distribution , Viscosity
13.
J Microencapsul ; 13(6): 689-99, 1996.
Article in English | MEDLINE | ID: mdl-8933354

ABSTRACT

MIcrospheres containing diclofenac sodium (DS) were prepared using carboxymethylcellulose (CMC) as the main support material (1.0, 2.0, 3.0% (w/v)) and aluminum chloride as the crosslinker. Drug to polymer ratios of 1:1, 1:2 and 1:4 were used to obtain a range of microspheres. The microspheres were then coated with an enteric coating material, Eudragit S-100, efficiency, % yield value, particle sizes an in-vitro dissolution behaviour were investigated. The surface of the enteric coated microspheres seemed to be all covered with Eudragit S-100 from scanning electron microscopy observation. It was also observed that increasing the CMC concentration led to an increase in the encapsulation efficiency, % yield value and particle size and decreased the release rate. Eudragit S-100 coating did not significantly alter the size but the release rate was significantly lower even when the lower concentration solution was used.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/chemistry , Carboxymethylcellulose Sodium/chemistry , Diclofenac/chemistry , Pharmaceutic Aids/chemistry , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Carboxymethylcellulose Sodium/administration & dosage , Chemistry, Pharmaceutical , Delayed-Action Preparations , Diclofenac/administration & dosage , Microscopy, Electron, Scanning , Microspheres , Particle Size , Pharmaceutic Aids/administration & dosage , Tablets, Enteric-Coated
14.
Pharm Dev Technol ; 1(2): 175-83, 1996 Jul.
Article in English | MEDLINE | ID: mdl-9552344

ABSTRACT

The objective of this investigation was to formulate and prepare sustained-action microcapsules of phenytoin sodium (diphenyl hydantoin sodium salt). Using ethylcellulose and methyl acrylic acid copolymers (Eudragit S-100 and L-100) as coating materials, microcapsules of phenytoin sodium were formulated by an organic phase separation and a granule coating method. The phase diagrams were used to study the phase separation in an ethylcellulose-petroleum ether-toluene system, and the effect of temperature and amount of petroleum ether on the ethylcellulose left in the organic solvent mixture was investigated. The phase diagrams showed that increase in temperature did not significantly affect the ethylcellulose residue, and 60 ml of nonsolvent was found adequate for microencapsulation. In vitro release of the formulated microcapsules and the commercially available preparations was performed in CO2-free distilled water using the USP XXIII rotating basket method, and the profiles were evaluated by Higuchi kinetics. Geometric mean diameters of the microparticles prepared by two different methods showed differences due to different core:wall ratios. A 4 x 5 factorial design was utilized and multiple regression was applied to the dependent variables (ethylcellulose content, percent dissolved) against the independent variables (amount of nonsolvent, temperature, core:wall ratio); the optimum phenytoin sodium-to-ethylcellulose ratio was 1:2.3. Utilizing second-order polynomial equations, response-surface graphs and contour plots pointed out the time necessary for 40%, 55%, and 70% release of phenytoin sodium. The desired release profiles were obtained with formulations E-5, ES-2 and ESL-2.


Subject(s)
Anticonvulsants/administration & dosage , Phenytoin/administration & dosage , Capsules , Cellulose , Delayed-Action Preparations , Drug Compounding , Excipients , Kinetics , Particle Size , Solubility
15.
J Microencapsul ; 13(2): 141-59, 1996.
Article in English | MEDLINE | ID: mdl-8999120

ABSTRACT

In this study microspheres of diclofenac sodium, an anti-inflammatory agent, were prepared by utilizing a natural polysaccharide, chitosan-H. The objective of this investigation was to sustain the action of diclofenac sodium and to show the effect of various conditions on release kinetics. For this reason factorial design experiments were performed. The independent variables in the 3(3) factorial design were chitosan-H concentration, tripolyphosphate concentration and stabilization time, and in the 3(2) factorial design were chitosan-H and tripolyphosphate concentrations. The dependent variables, t50% and the total drug content were investigated by the polynomial equations. The release profiles were evaluated kinetically and the best fit was obtained by the Higuchi equation.


Subject(s)
Chitin/analogs & derivatives , Diclofenac/administration & dosage , Chemistry, Pharmaceutical , Chitosan , Diclofenac/chemistry , Kinetics , Microspheres , Particle Size , Polyphosphates , Solubility , Surface Properties
16.
Pharmazie ; 50(4): 275-7, 1995 Apr.
Article in English | MEDLINE | ID: mdl-7792304

ABSTRACT

A biodegradable diclofenac sodium (DS) microsphere system using chitosan has been characterized and evaluated in vitro and in vivo. The particle size distribution and drug content was determined. The release rate data were investigated by using zero-order, first-order, Hixson-Crowel and Higuchi kinetics. The optimum DS-Chitosan microsphere formulation, empty chitosan microspheres, sustained release commercial product and plain drug were evaluated for pharmacological activity. The ulcerogenic index in rabbits was also determined.


Subject(s)
Diclofenac/administration & dosage , Animals , Chitin/analogs & derivatives , Chitosan , Delayed-Action Preparations , Diclofenac/adverse effects , Microspheres , Particle Size , Rabbits , Solubility , Stomach Ulcer/chemically induced , Stomach Ulcer/pathology
17.
J Microencapsul ; 11(6): 657-62, 1994.
Article in English | MEDLINE | ID: mdl-7884631

ABSTRACT

The possibility of reducing drug transfer across the placenta was tested in two of our previous studies. The aim of those studies was to demonstrate an alternative method of drug application during pregnancy which we think would yield a dual benefit, i.e. protecting the foetus from the harmful effects of drugs while curing the mother. The present study was planned as a continuation of the testing of the same idea and we tried to see the effect of albumin microsphere encapsulation of chloramphenicol on its transfer across the human placenta in vitro. Microspheres containing chloramphenicol were prepared according to the method previously described. The mean per cent encapsulation of chloramphenicol in albumin microspheres was found to be 42 +/- 4.3 per cent (n = 5) and the mean size of the albumin microspheres was 3.08 +/- 0.6 mm. In vitro stability of the drug-carrying microspheres was measured by dialysing them at 37 degrees C for 24 h. Chloramphenicol was released from the microspheres gradually leaving about 50 per cent of the entrapped drug in the microspheres after 1.5 h. About 20 per cent of the chloramphenicol was retained in the microspheres at 24 h postincubation. The persistence of the antibacterial effect of the released chloramphenicol is confirmed by antibiogramme tests. In the perfusions the initial free drug concentration was kept at 100 mg/ml.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Albumins/pharmacology , Chloramphenicol/administration & dosage , Chloramphenicol/pharmacokinetics , Placenta/metabolism , Biological Transport , Chemistry, Pharmaceutical , Chloramphenicol/pharmacology , Female , Humans , In Vitro Techniques , Microspheres , Particle Size , Perfusion , Pregnancy
18.
J Microencapsul ; 10(3): 309-17, 1993.
Article in English | MEDLINE | ID: mdl-8377088

ABSTRACT

Sustained action Isosorbide-5-mononitrate (IS-5-MN) microcapsules are prepared in order to overcome the tolerance developed in conventional preparations and to increase patient compliance. For this purpose, factorial design experiments are performed and microcapsules of IS-5-MN are formulated by the organic phase separation method using ethylcellulose with two different viscosities (10 and 45 cp) as coating material. The independent variables in the 2 x 3 x 3 factorial design are core: wall ratio, particle size and pH of the medium. The dependent variable, t50 percent is investigated by the second-order polynomial equation to establish the correlation between independent variables. By using the calculated equations, the response-surface graphs, from which various levels of independent variables could be predicted, are obtained. The in vitro release profiles of the formulated microcapsules and the commercially available preparations are obtained by using the rotating basket method. In vitro release is evaluated by zero-order, first-order, Hixson-Crowell and Higuchi release kinetics. The t50 percent values obtained from the Higuchi equation are used as response in the 2 x 3 x 3 factorial design experiments.


Subject(s)
Chemistry, Pharmaceutical/methods , Drug Compounding/methods , Isosorbide Dinitrate/analogs & derivatives , Delayed-Action Preparations , Drug Design , Isosorbide Dinitrate/administration & dosage , Isosorbide Dinitrate/chemistry , Particle Size
19.
J Microencapsul ; 10(3): 367-74, 1993.
Article in English | MEDLINE | ID: mdl-8377094

ABSTRACT

Chloramphenicol is an antibiotic which can pass across the human placenta and has teratogenic effects in the foetus. When this antibiotic is entrapped in albumin microspheres and administered to pregnant rats intravenously its placental transport is significantly lowered when compared with that of free drug. Drug modifications such as entrapment are suggested as an alternative way to prevent harmful effects of drugs in case of consumption during pregnancy.


Subject(s)
Chloramphenicol/administration & dosage , Chloramphenicol/pharmacokinetics , Maternal-Fetal Exchange , Placenta/metabolism , Animals , Carbon Radioisotopes , Female , Male , Microspheres , Pregnancy , Rats , Serum Albumin/administration & dosage , Serum Albumin/pharmacokinetics , Tissue Distribution
20.
Boll Chim Farm ; 130(2): 66-70, 1991 Feb.
Article in English | MEDLINE | ID: mdl-1873024

ABSTRACT

The preparation of albumin and gelatin microspheres with a tuberculostatic agent, rifampicin, was studied, and its in vivo distribution was investigated by providing its accumulation in the target organ lungs. The purpose of the study is to improve the effectiveness by injecting the microspheres intravenously with much smaller doses than normally required with generalized systemic administration, whilst reducing the systemic side effects. The emulsion polymerization method is applied in microsphere preparation, and glutaraldehyde is employed for albumin and formaldehyde for gelatin microspheres as the cross-linking agents. Biodistribution was determined by intravenous administration of particles of 25 to 27 microns 99mTc-labelled microspheres to Swiss albino mice. The radioactivity of the lungs was compared with the radioactivity of the liver, spleen, kidney, stomach and heart at 10, 30 and 60 min, and 6 and 24 h post-injection. The percentage accumulated was higher in the lungs than in the other organs for both albumin and gelatin microspheres, whereas free rifampicin accumulated mainly in the liver. To support the data of the in vivo distribution studies, the microspheres were histopathologically investigated after the intravenous injection to Swiss albino mice. After the microscopic determination of the lungs and liver, the spherical microspheres were observed after 10,30 and 60 min, and 6 and 24 h post-injection.


Subject(s)
Rifampin/pharmacokinetics , Animals , Gelatin , Humans , Mice , Microspheres , Rifampin/administration & dosage , Technetium Tc 99m Aggregated Albumin , Tissue Distribution
SELECTION OF CITATIONS
SEARCH DETAIL
...